TrialBlood2019

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Anton W Langerak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.